Two negatives don’t make a positive in patients with CRPC

Data from a small Phase II trial of cilengitide suggest that it  has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group. … READ MORE …